PolyPeptide Group H1 Revenue Surges 41.6% as Samsung Biologics Proposes Acquisition

The Quick Take

• PolyPeptide Group H1 2026 revenue surged 41.6% as metabolic drug demand accelerated peptide API outsourcing volumes
• EBITDA margin expanded to 20.7%, reflecting improved operational leverage across core peptide manufacturing facilities
• Samsung Biologics has proposed an acquisition of PolyPeptide Group, which upgraded its full-year 2026 guidance

PolyPeptide Group AG reported first-half 2026 revenue growth of 41.6% with EBITDA margin expanding to 20.7%, as surging demand for metabolic disease drugs drove outsourced peptide active pharmaceutical ingredient volumes sharply higher. The Swiss-listed contract manufacturer has emerged as a key beneficiary of the GLP-1 obesity drug production cycle, where pharmaceutical companies are aggressively expanding API sourcing to meet unprecedented patient demand. The company also upgraded its full-year 2026 guidance, reflecting management confidence in the durability of volume growth through the second half of the year as GLP-1 prescriptions continue to expand globally.

The proposed acquisition by Samsung Biologics positions PolyPeptide Group as a strategic consolidation target in the high-growth peptide CDMO space, where scale and manufacturing depth are decisive competitive advantages. Samsung Biologics, South Korea's dominant contract manufacturer, is seeking to expand beyond large-molecule biologics into the faster-growing peptide segment driven by the GLP-1 drug wave. Investors in PolyPeptide Group stand to benefit from an acquisition premium, while the deal could also prompt re-rating of comparable CDMOs including Lonza Group and Bachem Holding, which compete in adjacent peptide manufacturing niches across Europe and Asia.

The critical forward signal for PolyPeptide Group investors is the progression and terms of the Samsung Biologics acquisition proposal, including whether a formal offer materializes and at what premium to current market value. GLP-1 volume momentum at major pharmaceutical clients, including Novo Nordisk and Eli Lilly, will drive revenue visibility through H2 2026 and into 2027. Regulatory filings under Swiss takeover rules will set the formal deal timeline, while any competing bidder emergence could trigger additional upside. Macro currency factors between CHF and KRW will also influence the deal economics from the perspective of the Korean acquirer.

Synthesized from 1 source.